<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02883335</url>
  </required_header>
  <id_info>
    <org_study_id>RELSEP</org_study_id>
    <nct_id>NCT02883335</nct_id>
  </id_info>
  <brief_title>Lorraine Registry of Multiple Sclerosis</brief_title>
  <acronym>RelSEP</acronym>
  <official_title>Lorraine Registry of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lorraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RelSEP aims to register exhaustively every new case of multiple sclerosis (MS) occuring&#xD;
      in Lorraine a French region, and follow up on them for an indefinite duration, registering&#xD;
      disease evolution and intercurrent events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As every patient registry in France, the RelSEP is periodically (every four years) evaluated&#xD;
      by an independent committee.&#xD;
&#xD;
      The RelSEP interrogate multiple sources to insure its exhaustiveness :&#xD;
&#xD;
        -  every neurologists of Lorraine&#xD;
&#xD;
        -  MS patient network in Lorraine&#xD;
&#xD;
        -  health insurance data&#xD;
&#xD;
        -  PMSI (administrative French national database for hospitals)&#xD;
&#xD;
        -  biological and imagery services in Lorraine Procedures (automatic and manual) are used&#xD;
           to eliminate duplicates Once a patient has been identified its medical file are checked&#xD;
           by investigators in order to retrieve the relevant information.&#xD;
&#xD;
      New MS cases are confirmed by neurologists. Automatics (implemented in EDMUS software)and&#xD;
      manual checks are implemented in the registry database, looking for inconsistencies.&#xD;
&#xD;
      The following data are registered :&#xD;
&#xD;
        -  Name, birthname&#xD;
&#xD;
        -  Sex&#xD;
&#xD;
        -  Date of birth&#xD;
&#xD;
        -  Location (town)&#xD;
&#xD;
        -  Birth location (town)&#xD;
&#xD;
        -  Profession&#xD;
&#xD;
        -  Number of siblings&#xD;
&#xD;
        -  Marital status&#xD;
&#xD;
        -  Number of children&#xD;
&#xD;
        -  Date of onset&#xD;
&#xD;
        -  Date and nature of clinical manifestations&#xD;
&#xD;
        -  MRI reports&#xD;
&#xD;
        -  CSF analysis reports&#xD;
&#xD;
        -  Event-related potential reports&#xD;
&#xD;
        -  Impairment and disability evolution&#xD;
&#xD;
        -  Treatments (start and change of drug treatment)&#xD;
&#xD;
        -  Drugs related events&#xD;
&#xD;
        -  Cause of treatment discontinuation&#xD;
&#xD;
        -  Disease progression Every case has a follow up at least every two years.&#xD;
&#xD;
      The quality of data is evaluated by periodically auditing cases at random from our database.&#xD;
&#xD;
      An annual report on the main data (incidence and prevalence) of MS in Lorraine is produced.&#xD;
&#xD;
      Data are also used for observational studies on prognostic factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Anticipated">January 2030</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Years</target_duration>
  <primary_outcome>
    <measure>case occurence of multiple sclerosis</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EDSS score</measure>
    <time_frame>30 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational registry</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from multiple sclerosis in Lorraine&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having a confirmed multiple sclerosis diagnosis&#xD;
&#xD;
          -  Living in Lorraine (French region)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to be registered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Guillemin, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francis Guillemin, MD, PHD</last_name>
    <email>francis.guillemin@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Epstein, MD, MSc</last_name>
    <email>j.epstein@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIC 1433 Épidémiologie clinique, Inserm, Université de Lorraine, CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Epstein, MD, MSc</last_name>
      <email>j.epstein@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Brissart H, Morele E, Baumann C, Perf ML, Leininger M, Taillemite L, Dillier C, Pittion S, Spitz E, Debouverie M. Cognitive impairment among different clinical courses of multiple sclerosis. Neurol Res. 2013 Oct;35(8):867-72. doi: 10.1179/1743132813Y.0000000232. Epub 2013 Jun 19.</citation>
    <PMID>23816638</PMID>
  </reference>
  <reference>
    <citation>Brissart H, Sauvée M, Latarche C, Dillier C, Debouverie M. Integration of cognitive impairment in the expanded disability status scale of 215 patients with multiple sclerosis. Eur Neurol. 2010;64(6):345-50. doi: 10.1159/000322140. Epub 2010 Nov 13.</citation>
    <PMID>21071951</PMID>
  </reference>
  <results_reference>
    <citation>El Adssi H, Debouverie M, Guillemin F; LORSEP Group. Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method. Mult Scler. 2012 Sep;18(9):1244-50. Epub 2012 Feb 21.</citation>
    <PMID>22354740</PMID>
  </results_reference>
  <results_reference>
    <citation>Becker M, Latarche C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F. No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol. 2015 May 13;15:79. doi: 10.1186/s12883-015-0330-4.</citation>
    <PMID>25966681</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>August 18, 2018</last_update_submitted>
  <last_update_submitted_qc>August 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>GUILLEMIN Francis, MD</investigator_full_name>
    <investigator_title>Médecine coordonateur de module</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>open to partnership</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

